Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lonsurf
Pharma
FDA signs off on Takeda's colorectal cancer drug Fruzaqla
Takeda has scored an FDA approval for VEGF inhibitor Fruzaqla to treat adults with metastatic colorectal cancer (mCRC) as a third-line treatment.
Kevin Dunleavy
Nov 9, 2023 10:54am
Taiho wins FDA nod for stronger colorectal cancer regimen
Aug 2, 2023 4:17pm
Takeda, Hutchmed hook up on cancer drug for $1.13B
Jan 23, 2023 10:31am
China's reimbursement talks, Sun, GenScript—Fierce Pharma Asia
Jan 20, 2023 9:00am
Servier, Taiho's Lonsurf excels in colorectal cancer upgrade
Jan 18, 2023 3:50pm
